AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31401973 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg rabbit ATG
Number of subjects: 408
Study 31401973 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.0 mg/kg rabbit ATG
Number of subjects: 408
Study 29958863 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced image technique
Number of subjects: 59
Study 29958863 — intervention group
Group type: COMPARATOR
Intervention: Original image technique
Number of subjects: 59
Study 27895542 — intervention group
Group type: EXPERIMENTAL
Intervention: Tart cherry juice (CJ)
Number of subjects: 9
Study 27895542 — intervention group
Group type: COMPARATOR
Intervention: Placebo equivalent (PLA)
Number of subjects: 9
Study 24801768 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination (OFC)
Number of subjects: 444
Study 24801768 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 444
Study 22578975 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy separation from CPB (no support or one vasoactive agent/inotrope)
Number of subjects: 2331
Study 22578975 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult separation from CPB (two drug types used)
Number of subjects: 2331
Study 22578975 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex separation from CPB (first weaning process failed or mechanical devices required)
Number of subjects: 2331
Study 19507027 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated, delayed-release peppermint oil (Colpermin)
Number of subjects: 90
Study 19507027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 18029880 — intervention group
Group type: EXPERIMENTAL
Intervention: New splenic grading system
Number of subjects: 400
Study 18029880 — intervention group
Group type: COMPARATOR
Intervention: AAST injury scale
Number of subjects: 400
Study 16178825 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised training for GP trainers
Number of subjects: 47
Study 16178825 — intervention group
Group type: COMPARATOR
Intervention: No specific programme for control group
Number of subjects: 47
Study 12037657 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diet wellness program
Number of subjects: 78
Study 12037657 — intervention group
Group type: COMPARATOR
Intervention: Traditional diet program
Number of subjects: 78
Study 12037657 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study 12037657 — intervention group
Group type: COMPARATOR
Intervention: Diet group
Number of subjects: 78
Study 12037657 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diet group
Number of subjects: 78
Study 10459961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial 131I-lipiodol (1850 MBq)
Number of subjects: 43
Study 10459961 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (control)
Number of subjects: 43
Study 7792281 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise confined to early pregnancy
Number of subjects: 0
Study 7792281 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise throughout pregnancy
Number of subjects: 0
Study 7792281 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (no exercise)
Number of subjects: 0
Study 2193303 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (betamethasone)
Number of subjects: 0
Study 2193303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 760589 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxazepam
Number of subjects: 40
Study 760589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30670227 — intervention group
Group type: EXPERIMENTAL
Intervention: 3RP‐NF (Relaxation Response Resiliency Program for NF)
Number of subjects: 31
Study 28659136 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight group (BMI > normal)
Number of subjects: 95126
Study 28659136 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group (BMI > overweight)
Number of subjects: 95126
Study 28659136 — intervention group
Group type: EXPERIMENTAL
Intervention: <1-15 units/week alcohol consumption
Number of subjects: 95126
Study 28659136 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-20 units/week alcohol consumption
Number of subjects: 95126
Study 28659136 — intervention group
Group type: EXPERIMENTAL
Intervention: >=21 units/week alcohol consumption
Number of subjects: 95126
Study 28659136 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women consuming >=21 units/week
Number of subjects: 95126
Study 28659136 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women drinking <1-15 units/week
Number of subjects: 95126
Study 28659136 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal BMI consuming >=21 units/week
Number of subjects: 95126
Study 25772548 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg as add-on to sulphonylurea
Number of subjects: 1000
Study 25772548 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg as add-on to sulphonylurea
Number of subjects: 1000
Study 25772548 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg as add-on to other therapies
Number of subjects: 1000
Study 25772548 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg as add-on to other therapies
Number of subjects: 1000
Study 25772548 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg and 25 mg
Number of subjects: 1000
Study 23369827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate 1 g/d
Number of subjects: 151
Study 23369827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate 6 g/d
Number of subjects: 151
Study 23369827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate 8 g/d
Number of subjects: 151
Study 21079990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice vest combined with hand/forearm immersion (VEST + W)
Number of subjects: 8
Study 21079990 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand/forearm immersion (W)
Number of subjects: 8
Study 21079990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice vest (VEST)
Number of subjects: 8
Study 21079990 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 8
Study 21079990 — intervention group
Group type: EXPERIMENTAL
Intervention: VEST + W and W
Number of subjects: 8
Study 21079990 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling conditions (VEST + W and W)
Number of subjects: 8
Study 21079990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice vests and hand/forearm immersion
Number of subjects: 8
Study 21079990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice vests combined with hand/forearm immersion
Number of subjects: 8
Study 20122033 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping and communication support (CCS) intervention
Number of subjects: 210
Study 17491177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Phone Intervention (CPI)
Number of subjects: 95
Study 17491177 — intervention group
Group type: COMPARATOR
Intervention: Recommended Standard of Care (RSOC)
Number of subjects: 95
Study 15677430 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined T4 plus T3
Number of subjects: 40
Study 15677430 — intervention group
Group type: COMPARATOR
Intervention: T4 alone
Number of subjects: 40
Study 11696916 — intervention group
Group type: EXPERIMENTAL
Intervention: 830 nm laser irradiation (4.8 J per session)
Number of subjects: 12
Study 11696916 — intervention group
Group type: COMPARATOR
Intervention: Sham laser treatment (control group)
Number of subjects: 12
Study 11967825 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 86
Study 11967825 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 86
Study 11967825 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 86
Study 8633373 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 48
Study 8633373 — intervention group
Group type: COMPARATOR
Intervention: No pravastatin (Control)
Number of subjects: 48
Study 1730427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal radioactive phosphorus
Number of subjects: 93
Study 1730427 — intervention group
Group type: COMPARATOR
Intervention: Oral melphalan
Number of subjects: 93
Study 1730427 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 93
Study 6236576 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide 40 micrograms
Number of subjects: 11
Study 6236576 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide 200 micrograms or more
Number of subjects: 11
Study 6236576 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 30595035 — intervention group
Group type: EXPERIMENTAL
Intervention: Caponisation
Number of subjects: 200
Study 30595035 — intervention group
Group type: COMPARATOR
Intervention: Cockerels (control)
Number of subjects: 200
Study 30595035 — intervention group
Group type: EXPERIMENTAL
Intervention: Older capons (24 and 28 weeks)
Number of subjects: 200
Study 29748907 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (VDRA) 0.25-0.5 µg once a day
Number of subjects: 0
Study 29748907 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (VDRA) 0.25-0.5 µg once a day + Lanthanum carbonate (LC) 250 mg once a day
Number of subjects: 0
Study 26459503 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational nursing home visits
Number of subjects: 123
Study 26459503 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 123
Study 24670828 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Eluting Balloon (DEB)
Number of subjects: 50
Study 24670828 — intervention group
Group type: COMPARATOR
Intervention: Conventional Angioplasty Balloon (PTA)
Number of subjects: 50
Study 22452942 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron transdermal system (GTDS)
Number of subjects: 240
Study 22452942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous granisetron
Number of subjects: 240
Study 22452942 — intervention group
Group type: COMPARATOR
Intervention: Oral moxifloxacin (active control)
Number of subjects: 240
Study 22452942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 21156079 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion
Number of subjects: 0
Study 21156079 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone/salmeterol (seretide)
Number of subjects: 0
Study 16949264 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol as-needed (3.95% asthma exacerbations; 7 of 177 patients)
Number of subjects: 359
Study 16949264 — intervention group
Group type: COMPARATOR
Intervention: Formoterol twice daily (3.45% asthma exacerbations; 6 of 174 patients)
Number of subjects: 359
Study 16949264 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol as-needed
Number of subjects: 359
Study 16949264 — intervention group
Group type: COMPARATOR
Intervention: Formoterol twice daily supplemented by salbutamol
Number of subjects: 359
Study 16318440 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 1491
Study 16318440 — intervention group
Group type: COMPARATOR
Intervention: 5-Fluorouracil
Number of subjects: 1491
Study 16318440 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 1491
Study 12127382 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise only
Number of subjects: 1140
Study 12127382 — intervention group
Group type: EXPERIMENTAL
Intervention: Education only
Number of subjects: 1140
Study 12127382 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and education combined
Number of subjects: 1140
Study 12127382 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1140
Study 9667590 — intervention group
Group type: COMPARATOR
Intervention: Interferon-beta1b (IFN-beta1b) alone
Number of subjects: 0
Study 9667590 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta1b (IFN-beta1b) in combination with pentoxifylline (PTX)
Number of subjects: 0
Study 8537138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 8 mg/kg body weight once daily for 5 days
Number of subjects: 151
Study 8537138 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 20,000 I.U./kg body weight t.i.d. for 10 days
Number of subjects: 151
Study 1973545 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 0
Study 1973545 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptics
Number of subjects: 0
Study 30508156 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib followed by cetuximab (R-C arm)
Number of subjects: 101
Study 30508156 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab followed by regorafenib (C-R arm)
Number of subjects: 101
Study 30508156 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib in R-C versus cetuximab in C-R
Number of subjects: 101
Study 30508156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab in R-C versus regorafenib in C-R
Number of subjects: 101
Study 30508156 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life scores during the entire treatment period
Number of subjects: 101
Study 28704520 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation exercise with correcting information about MMR vaccine and autism
Number of subjects: 585
Study 28704520 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation exercise without correcting information
Number of subjects: 585
Study 28704520 — intervention group
Group type: COMPARATOR
Intervention: Control passage about bird feeding with correcting information about MMR vaccine and autism
Number of subjects: 585
Study 28704520 — intervention group
Group type: COMPARATOR
Intervention: Control condition reflecting on least-personally-important values
Number of subjects: 585
Study 26216229 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel method for wear analysis in tantalum cups
Number of subjects: 46
Study 26216229 — intervention group
Group type: COMPARATOR
Intervention: Gold standard RSA
Number of subjects: 46
Study 23247973 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyreogutt® mono (Lycopus europaeus) in prolective assessment for 4 weeks
Number of subjects: 403
Study 23247973 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyreogutt® mono (Lycopus europaeus) in retrolective assessment for at least one course (4 weeks) during the previous 2 years
Number of subjects: 403
Study 23247973 — intervention group
Group type: COMPARATOR
Intervention: Control cohort receiving no drug treatment
Number of subjects: 403
Study 21307136 — intervention group
Group type: COMPARATOR
Intervention: Active controls (VO2max > 40 ml/kg · min)
Number of subjects: 58
Study 21307136 — intervention group
Group type: COMPARATOR
Intervention: Healthy sedentary controls (FH-)
Number of subjects: 58
Study 21307136 — intervention group
Group type: COMPARATOR
Intervention: Healthy sedentary controls (FH+)
Number of subjects: 58
Study 21307136 — intervention group
Group type: COMPARATOR
Intervention: Obese participants
Number of subjects: 58
Study 21307136 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM
Number of subjects: 58
Study 19041438 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 41
Study 19041438 — intervention group
Group type: COMPARATOR
Intervention: DMPA
Number of subjects: 41
Study 17109685 — intervention group
Group type: EXPERIMENTAL
Intervention: Talpha1 therapy (1.6 mg, two times a week for 26 weeks)
Number of subjects: 98
Study 17109685 — intervention group
Group type: EXPERIMENTAL
Intervention: Talpha1 therapy (1.6 mg, two times a week for 52 weeks)
Number of subjects: 98
Study 17109685 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment for 18 months)
Number of subjects: 98
Study 17109685 — intervention group
Group type: EXPERIMENTAL
Intervention: Talpha1 therapy
Number of subjects: 98
Study 17109685 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study 15569282 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus education by telephone (155 children)
Number of subjects: 310
Study 15569282 — intervention group
Group type: COMPARATOR
Intervention: Standard care (155 children)
Number of subjects: 310
Study 11789123 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of St. John's wort extract WS 5572 daily
Number of subjects: 2166
Study 11789123 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg of St. John's wort extract WS 5572 daily
Number of subjects: 2166
Study 9247843 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathic treatment (Aconitum napellus, Apis mellifica, Belladonna, Capsicum, Chamomilla, Kalium bichromicum, Lachesis, Lycopodium, Mercurius solubilis, Okoubaka, Pulsatilla, Silicea)
Number of subjects: 131
Study 9247843 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (nasal drops, antibiotics, secretolytics and/or antipyretics)
Number of subjects: 131
Study 9247843 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathic treatment
Number of subjects: 131
Study 9247843 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 131
Study 7967986 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight support and standing on a moving treadmill
Number of subjects: 0
Study 7967986 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily training
Number of subjects: 0
Study 7967986 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme
Number of subjects: 0
Study 3583229 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (330 mg) and dipyridamole (75 mg) taken three times daily for three weeks
Number of subjects: 6
Study 3583229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30957446 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion at Shenque (CV 8) and warm needling at Guanyuan (CV 4) and Sanyinjiao (SP 6)
Number of subjects: 120
Study 30957446 — intervention group
Group type: COMPARATOR
Intervention: Warm needling at Guanyuan (CV 4) and Sanyinjiao (SP 6)
Number of subjects: 120
Study 28520519 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-based contrast
Number of subjects: 1119
Study 28520519 — intervention group
Group type: COMPARATOR
Intervention: Water-based contrast
Number of subjects: 1119
Study 25886810 — intervention group
Group type: EXPERIMENTAL
Intervention: External stenting
Number of subjects: 30
Study 25886810 — intervention group
Group type: COMPARATOR
Intervention: Nonstented SVG
Number of subjects: 30
Study 23177399 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered interview (PCI)
Number of subjects: 9
Study 23177399 — intervention group
Group type: COMPARATOR
Intervention: Clinician-centered interview (CCI)
Number of subjects: 9
Study 21982657 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoblasts (400 million)
Number of subjects: 23
Study 21982657 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoblasts (800 million)
Number of subjects: 23
Study 21982657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 18163420 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 10057
Study 18163420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10057
Study 17177154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta‐1a 15 micrograms once a week
Number of subjects: 16
Study 17177154 — intervention group
Group type: COMPARATOR
Intervention: No disease-modifying therapy
Number of subjects: 16
Study 12915289 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 980
Study 12915289 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 980
Study 10972697 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alpha to achieve hemoglobin levels of 10 g/dL
Number of subjects: 146
Study 10972697 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alpha to achieve hemoglobin levels of 13.5 g/dL
Number of subjects: 146
Study 10972697 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of hemoglobin
Number of subjects: 146
Study 8776187 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin and thymopentin for immunomodulation (Group B)
Number of subjects: 20
Study 8776187 — intervention group
Group type: COMPARATOR
Intervention: Control group A (no intervention)
Number of subjects: 20
Study 1474076 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein (LP) = 0.86 g protein.kg‐1.day‐1 for 13 days
Number of subjects: 0
Study 1474076 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate protein (MP) = 1.40 g protein.kg‐1.day‐1 for 13 days
Number of subjects: 0
Study 1474076 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein (HP) = 2.40 g protein.kg‐1.day‐1 for 13 days
Number of subjects: 0
Study 1474076 — intervention group
Group type: COMPARATOR
Intervention: Low protein (LP) for sedentary subjects (S)
Number of subjects: 0
Study 1474076 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein (HP) for sedentary subjects (S)
Number of subjects: 0
Study 6379859 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigason (vitamin A-acid analog) for 8 months
Number of subjects: 73
Study 6379859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 6379859 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigason
Number of subjects: 73
Study 30062823 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM
Number of subjects: 47
Study 27491533 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 108
Study 27491533 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitisation and Reprocessing (EMDR) therapy
Number of subjects: 108
Study 26591355 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishen Qingre Huashi Recipe (YQHR)
Number of subjects: 121
Study 26591355 — intervention group
Group type: COMPARATOR
Intervention: Losartan Potassium Tablet (50 mg once per day)
Number of subjects: 121
Study 23659074 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin
Number of subjects: 0
Study 20506254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 300 mg
Number of subjects: 264
Study 20506254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 700 mg
Number of subjects: 264
Study 20506254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 1000 mg
Number of subjects: 264